Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing nivolumab versus temozolomide, each with radiation, in newly diagnosed glioblastoma; study completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Temozolomide (Temozolomide)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Brain Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-02-03